ΠΛΕΟΝΕΚΤΗΜΑΤΑ ΚΑΙ ΕΠΙΠΛΟΚΕΣ ΑΠΟ ΤΗ ΧΟΡΗΓΗΣΗ ΝΕΩΤΕΡΩΝ ΑΝΤΙΠΗΚΤΙΚΩΝ ( NOACS) ΣΚΕΥΑΣΜΑΤΩΝ ΣΕ ΓΗΡΙΑΤΡΙΚΟΥΣ ΑΣΘΕΝΕΙΣ ΜΕ ΚΑΡΔΙΟ-ΑΝΑΠΝΕΥΣΤΙΚΑ ΝΟΣΗΜΑΤΑ
Fotini Kolentsi, Theodosios Kokkios
Friday, October 1, 2021
Publication year:
2021
Authors:
- Kolentsi Fotini, Nurse, MSc in Management of Health Units, Registered Nurse in Pathology, Head Nurse of the Pathology-Cardiology Department of the General Hospital of Kefalonia
- Kokkios Theodosios, Nurse, MSc in Management of Health Units, MSc in Management of Aging and Chronic Diseases, Registered Nurse in Public Health / Community Nursing (candidate), Nursing Unit of Agrinio
Keywords index:
Pages: 231-238
Abstract:
IIntroduction: The number of patients taking anticoagulants due to the increased incidence of coronary heart disease has increased in recent decades. Newer anticoagulants have recently been used in the treatment of atrial fibrillation, pulmonary embolism and deep vein thrombosis. Aim: The purpose of this review study was to highlight the benefits and complications of administering newer anticoagulants to geriatric patients with cardiorespiratory disease. Material-Methods: Data from studies, reviews and scientific articles in Pubmed and Mednet databases were used to write this review. Results: The calculation of the hemorrhagic risk as well as the ischemic events of the patients is of great importance in the decision-making for the individualization of the anticoagulation treatment. Newer oral anticoagulants offer better safety, easier use and effectiveness with the main advantage being the net clinical benefit over vitamin K blockers which increases with age in patients with Atrial Fibrillation. Conclusion: Successful anticoagulant action is determined by scientifically balancing the risk of thrombosis and its complication of bleeding, calculating the risk of bleeding and ischemic events in patients, while newer oral anticoagulants offer better safety, easier use and effectiveness.
Download PDF
